Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals reported a net loss of $1.25 million for the second quarter of 2026 and $2.06 million for the six months ended June 30, 2026. The company's cash balance decreased to $1.63 million, and it issued a going concern warning due to recurring losses and negative cash flows. To address funding needs, Hepion completed a $0.7 million private placement in April 2026 and a $3.1 million offering in July 2026. The company also entered into a license agreement for liver disease diagnostic assets and signed new employment agreements with its Executive Chairman and CEO.

Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors for a private placement offering. The company issued an aggregate of 61,100,000 shares of common stock and warrants to purchase an equal number of shares, generating gross proceeds of $3,055,000. The offering price was $0.05 per share, with warrants exercisable at $0.06 per share for five years. The transaction closed on August 3, 2026.

Hepion Pharmaceuticals, Inc. announced the appointment of Danina Fisher and Gary S. Stetz, II to its Board of Directors, effective July 1, 2026. The company noted that Gary S. Stetz, II is the son of Gary Stetz, the Interim Chief Executive Officer, but otherwise there are no other arrangements or family relationships.

Hepion Pharmaceuticals announced a significant leadership change with Dr. Kaouthar Lbiati resigning as CEO and Gary Stetz being appointed as the new CEO, alongside Vincent LoPriore as Executive Chairman. The company also reported a reduced net loss of $(0.81) million for Q1 2026, a substantial improvement from $(6.11) million in Q1 2025. This comes as the company pivots its focus from drug therapy to medical diagnostics, evidenced by a recent intellectual property license agreement with Cirna Diagnostics. Despite the improved financials, the company noted substantial doubt about its ability to continue as a going concern without additional capital, though it secured $700,000 in a private placement post-quarter end.

Hepion Pharmaceuticals, Inc. announced its Annual Meeting of Stockholders on June 17, 2026, where key proposals include the election of five directors and the ratification of Grassi & Co. as the independent auditor. A significant proposal involves amending the 2023 Omnibus Equity Incentive Plan to increase the number of shares issuable from 200,000 to 8,000,000, which could lead to substantial dilution. The filing also detailed the director nominees and corporate governance practices.

Hepion Pharmaceuticals, Inc. has entered into a Securities Purchase Agreement with various purchasers. Under this agreement, the company intends to issue and sell its securities to these purchasers. The transaction is structured as a private placement, utilizing exemptions from registration requirements under Section 4(a)(2) and/or Regulation D of the Securities Act.

Hepion Pharmaceuticals, Inc. entered into a separation agreement with its former CEO, Dr. Kaouthar Lbiati, on April 13, 2026. The agreement includes a severance payment of $225,000, a pro-rata cash bonus of $30,625, and 6 months of COBRA payment reimbursements. Dr. Lbiati also resigned from the company's board of directors on the same date.